ABCL-981: Comparative Efficacy and Safety of Available CD19-Directed Chimeric Antigen Receptor T-Cell Therapies for Treatment of Relapsed/Refractory Large B-Cell Lymphomas: A Network Meta-Analysis

Authors

• Muhammad Zain Raza
• Hafiz Muhammad Ehsan Arshad
• Maryam Maqsood, Rochester Regional HealthFollow
• Musab Maqsood
• Anas Babar
• Omar Abdullah Gill

Department

Internal Medicine

Document Type

Conference Proceeding

Publication Title

Clinical Lymphoma Myeloma and Leukemia

Conference Name

Society of Hematologic Oncology (SOHO) Annual Meeting

Conference Date

2026-09-09 - 2026-09-12

First Page

S932

DOI

10.1016/S2152-2650(26)02609-1

Volume

26

Issue

Supplement 1

Publication Date

8-1-2026

Recommended Citation

Raza, M. Z., Arshad, H. M., Maqsood, M., Maqsood, M., Babar, A., & Gill, O. A. (2026). ABCL-981: Comparative Efficacy and Safety of Available CD19-Directed Chimeric Antigen Receptor T-Cell Therapies for Treatment of Relapsed/Refractory Large B-Cell Lymphomas: A Network Meta-Analysis. Clinical Lymphoma Myeloma and Leukemia, 26 (Supplement 1), S932. https://doi.org/10.1016/S2152-2650(26)02609-1